NURO Stock Overview A commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
NeuroMetrix, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for NeuroMetrix Historical stock prices Current Share Price US$4.05 52 Week High US$4.73 52 Week Low US$2.66 Beta 2.21 1 Month Change 3.85% 3 Month Change -10.99% 1 Year Change 35.00% 3 Year Change -89.41% 5 Year Change -89.34% Change since IPO -100.00%
Recent News & Updates
NeuroMetrix, Inc. Announces Board and Committee Changes Jan 01 electroCore, Inc. (NasdaqCM:ECOR) entered into an agreement and plan of merger to acquire NeuroMetrix, Inc. (NasdaqCM:NURO). Dec 18
Third quarter 2024 earnings released: US$0.75 loss per share (vs US$1.66 loss in 3Q 2023) Nov 05
Second quarter 2024 earnings released: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023) Aug 07
NeuroMetrix, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Aug 01
First quarter 2024 earnings released: US$1.67 loss per share (vs US$1.64 loss in 1Q 2023) May 17 See more updates
NeuroMetrix, Inc. Announces Board and Committee Changes Jan 01 electroCore, Inc. (NasdaqCM:ECOR) entered into an agreement and plan of merger to acquire NeuroMetrix, Inc. (NasdaqCM:NURO). Dec 18
Third quarter 2024 earnings released: US$0.75 loss per share (vs US$1.66 loss in 3Q 2023) Nov 05
Second quarter 2024 earnings released: US$0.75 loss per share (vs US$1.56 loss in 2Q 2023) Aug 07
NeuroMetrix, Inc. to Report Q2, 2024 Results on Aug 06, 2024 Aug 01
First quarter 2024 earnings released: US$1.67 loss per share (vs US$1.64 loss in 1Q 2023) May 17 NeuroMetrix, Inc. has completed a Follow-on Equity Offering in the amount of $0.692831 million.
NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024 Mar 28
NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy Mar 15
New major risk - Shareholder dilution Feb 29 RS Fund Discloses its Views on NeuroMetrix
Full year 2023 earnings released: US$6.08 loss per share (vs US$4.96 loss in FY 2022) Feb 23
NeuroMetrix, Inc. to Report Q4, 2023 Results on Feb 22, 2024 Feb 16
NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy Dec 05
Third quarter 2023 earnings released: US$0.21 loss per share (vs US$0.23 loss in 3Q 2022) Oct 27
New minor risk - Share price stability Oct 27
NeuroMetrix, Inc. to Report Q3, 2023 Results on Oct 26, 2023 Oct 24
NeuroMetrix Receives Non-Compliance Notice From Nasdaq Aug 12
NeuroMetrix, Inc. to Report Q2, 2023 Results on Jul 27, 2023 Jul 23
NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia Jul 12
NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting Jun 08
NeuroMetrix, Inc. Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy Jun 01
First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2022) May 04
Full year 2022 earnings released: US$0.62 loss per share (vs US$0.45 loss in FY 2021) Feb 24
NeuroMetrix, Inc. to Report Q4, 2022 Results on Feb 23, 2023 Feb 17
NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy Jan 25
NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy Jan 24
Insufficient new directors Nov 16
NeuroMetrix, Inc. to Introduce Quell Fibromyalgia At the American College of Rheumatology 2022 Annual Meeting Nov 09
NeuroMetrix, Inc. Announces Strategic Launch of Quell Fibromyalgia Nov 04
Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.12 loss in 3Q 2021) Oct 22
NeuroMetrix reports Q3 results Oct 20
NeuroMetrix, Inc. to Report Q3, 2022 Results on Oct 20, 2022 Oct 13
NeuroMetrix: Strong Unit Economics, Accelerating Growth; Possibly Worth $15 In 5 Years Sep 23
Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales Sep 02
Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2021) Jul 22
NeuroMetrix GAAP EPS of -$0.17, revenue of $2.1M Jul 21
NeuroMetrix, Inc. to Report Q2, 2022 Results on Jul 21, 2022 Jul 15
NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022 Jun 29
NeuroMetrix, Inc. Reports Quell(R) Wearable Neuromodulation Device Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia May 20
We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely May 11
Insufficient new directors Apr 27
NeuroMetrix, Inc. to Report Q1, 2022 Results on Apr 26, 2022 Apr 20
NeuroMetrix, Inc. Reports That Quell® Wearable Neuromodulator to Be Evaluated in Post-Acute Covid-19 Syndrome Feb 25
Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind Jan 29
NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology Jan 19
Here's Why We're Not Too Worried About NeuroMetrix's (NASDAQ:NURO) Cash Burn Situation Jan 19
Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.068 loss in 3Q 2020) Oct 23
NeuroMetrix: Solving Unmet Needs In Diagnostics And Therapeutic Neurostimulation Sep 09
Senior VP recently sold US$528k worth of stock Aug 28
Senior VP recently sold US$271k worth of stock Aug 15
Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.28 loss in 2Q 2020) Jul 24
We're Hopeful That NeuroMetrix (NASDAQ:NURO) Will Use Its Cash Wisely Jul 21
NeuroMetrix, Inc. Announces Quell Technology Jun 16
NeuroMetrix Announces Top-Line Results from a Randomized Controlled Trial of Quell for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences Jun 10
First quarter 2021 earnings released: US$0.016 loss per share (vs US$0.45 loss in 1Q 2020) Apr 26
NeuroMetrix, Inc., Annual General Meeting, Apr 27, 2021 Mar 17
Full year 2020 earnings released: US$0.55 loss per share (vs US$3.90 loss in FY 2019) Jan 30
NeuroMetrix (NASDAQ:NURO) Is In A Good Position To Deliver On Growth Plans Jan 27
NeuroMetrix, Inc. to Report Q4, 2020 Results on Jan 28, 2021 Jan 23
New 90-day high: US$3.76 Jan 16
New 90-day high: US$3.05 Dec 23
New 90-day high: US$1.86 Nov 24
Third quarter earnings released Oct 23
NeuroMetrix, Inc. to Report Q3, 2020 Results on Oct 22, 2020 Oct 16
NeuroMetrix, Inc. Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-The-Counter Pain Relief Device Sep 23
New 90-day low - US$1.72 Aug 28
NeuroMetrix, Inc. to Report Q2, 2020 Results on Jul 23, 2020 Jul 18 Shareholder Returns NURO US Medical Equipment US Market 7D 2.0% 3.7% 3.2% 1Y 35.0% 12.4% 24.2%
See full shareholder returns
Return vs Market: NURO exceeded the US Market which returned 24.2% over the past year.
Price Volatility Is NURO's price volatile compared to industry and market? NURO volatility NURO Average Weekly Movement 6.8% Medical Equipment Industry Average Movement 8.7% Market Average Movement 6.5% 10% most volatile stocks in US Market 18.9% 10% least volatile stocks in US Market 3.2%
Stable Share Price: NURO has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NURO's weekly volatility (7%) has been stable over the past year.
About the Company NeuroMetrix, Inc., a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons.
Show more NeuroMetrix, Inc. Fundamentals Summary How do NeuroMetrix's earnings and revenue compare to its market cap? NURO fundamental statistics Market cap US$8.27m Earnings (TTM ) -US$7.68m Revenue (TTM ) US$3.77m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NURO income statement (TTM ) Revenue US$3.77m Cost of Revenue US$1.57m Gross Profit US$2.20m Other Expenses US$9.88m Earnings -US$7.68m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -3.76 Gross Margin 58.40% Net Profit Margin -203.71% Debt/Equity Ratio 0%
How did NURO perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/19 08:31 End of Day Share Price 2025/01/17 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources NeuroMetrix, Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Robert Wasserman Dawson James Securities Andrew Fein H.C. Wainwright & Co. Anthony Vendetti Maxim Group
Show 2 more analysts 
